Nov 27, 2019
UCLA Geneticist Steve Horvath has led a small clinical study that effectively reversed the participant’s epigenetic clock for what appears to be about 2.5 years as reported in Nature. The study involved a combination of drugs and growth hormones. Patients were treated with a combination of growth hormone and two diabetes medications which appeared to have worked—also rejuvenating the participant’s immune systems. The participating scientists found themselves surprised by the results.
The study actually started back in 2015 when Gregory Fahy, the chief scientific officer and co-founder of Intervene Immune in Los Angeles, the study sponsor. An immunologist by profession, Fahy requested that Horvath analyze the results to assess the impact on the patients’ epigenetic clock or biological age reported Newsweek. The study went on for a year and involved nine healthy participants. They were administered a cocktail of three common drugs—growth hormone and two diabetes medications. Called the Thymus Regeneration, Immunorestoration and Insulin Mitigation (TRIIM) trial, 9 white men participated—between the ages of 51 and 65 years of age. The study was approved by the FDA in May 2015. It was conducted at Stanford Medical Center in Palo Alto, CA.
To reach out to Dr. Fahy at Intervene Immune go here